Localization of CD44 and CD90 positive cells to the invasive front of breast tumors

Vera S. Donnenberg, Albert D. Donnenberg, Ludovic Zimmerlin, Rodney J. Landreneau, Rohit Bhargava, Ryan A. Wetzel, Per Basse, Adam M. Brufsky

Research output: Contribution to journalArticle

Abstract

Background: A variety of markers have been proposed to identify breast cancer stem cells. Here, we used immunohistostaining and flow cytometry to analyze their interrelationships and to sort cells for tumorigenicity studies. Methods: Cytokeratin, CD44, and CD90 were localized to primary breast cancer and normal breast (NB) tissue by immunohistostaining and related to CD117 and CD133 expression by flow cytometry. Immunodeficient NOD.CB17-Prkdcscid/J and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice were used to test tumorigenicity of sorted CD90+ low-light scatter, CD90+ high-light scatter, and CD90neg tumor cells. Results: NB basal cells coexpressed CD44 and CD90. As cells transited luminally, CD44 was retained and downmodulated, and CD90 was lost and cytokeratin increased. In breast tumors, basal-like CD44+/ CD90+ cells were localized to the tumor periphery, adjacent to CD90+ stroma. Like normal luminal cells, interior tumor cells were CD44+/CD90-. Immunophenotyping (CD44/CD90/CD117/CD133) of cytokeratin+ cells revealed no significant difference in expression between tumors and tumor-free breast. In both, CD133 was distributed approximately equally among CD44/CD90 subsets, whereas CD117 expression was highest in the basal-associated CD44+/CD90+ subset. Sorted CD90+ pleural effusion cells with lymphoid light scatter, 49% of which were CD44+, were uniquely tumorigenic in immunodeficient mice (100 cells/injection). Conclusions: Our data demonstrate that all tumors contain a small population of CD44+/CD90+ cells, mimicking the phenotype of ductal-basal cells. These are localized to the tumor periphery, adjacent to CD90+ stroma. Among the nonhematopoietic, nonmesothelial cells found in metastatic pleural effusions, low-light scatter CD90+ cells are most potently tumorigenic, compared to high-scatter CD90+ cells and CD90- cells.

Original languageEnglish (US)
Pages (from-to)287-301
Number of pages15
JournalCytometry Part B - Clinical Cytometry
Volume78
Issue number5
DOIs
StatePublished - Sep 2010
Externally publishedYes

Fingerprint

Breast Neoplasms
Keratins
Light
Neoplasms
Pleural Effusion
Flow Cytometry
Carcinogenicity Tests
Immunophenotyping
Neoplastic Stem Cells
Breast
Lymphocytes
Phenotype
Injections

Keywords

  • Breast cancer
  • Cancer stem cells
  • CD117
  • CD133
  • CD44
  • CD90
  • Cytokeratin
  • Flow cytometry
  • Immunofluorescence
  • Immunohistochemistry

ASJC Scopus subject areas

  • Cell Biology
  • Histology
  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Donnenberg, V. S., Donnenberg, A. D., Zimmerlin, L., Landreneau, R. J., Bhargava, R., Wetzel, R. A., ... Brufsky, A. M. (2010). Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. Cytometry Part B - Clinical Cytometry, 78(5), 287-301. https://doi.org/10.1002/cyto.b.20530

Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. / Donnenberg, Vera S.; Donnenberg, Albert D.; Zimmerlin, Ludovic; Landreneau, Rodney J.; Bhargava, Rohit; Wetzel, Ryan A.; Basse, Per; Brufsky, Adam M.

In: Cytometry Part B - Clinical Cytometry, Vol. 78, No. 5, 09.2010, p. 287-301.

Research output: Contribution to journalArticle

Donnenberg, VS, Donnenberg, AD, Zimmerlin, L, Landreneau, RJ, Bhargava, R, Wetzel, RA, Basse, P & Brufsky, AM 2010, 'Localization of CD44 and CD90 positive cells to the invasive front of breast tumors', Cytometry Part B - Clinical Cytometry, vol. 78, no. 5, pp. 287-301. https://doi.org/10.1002/cyto.b.20530
Donnenberg, Vera S. ; Donnenberg, Albert D. ; Zimmerlin, Ludovic ; Landreneau, Rodney J. ; Bhargava, Rohit ; Wetzel, Ryan A. ; Basse, Per ; Brufsky, Adam M. / Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. In: Cytometry Part B - Clinical Cytometry. 2010 ; Vol. 78, No. 5. pp. 287-301.
@article{72a291d9eed04c46bc832281f213a342,
title = "Localization of CD44 and CD90 positive cells to the invasive front of breast tumors",
abstract = "Background: A variety of markers have been proposed to identify breast cancer stem cells. Here, we used immunohistostaining and flow cytometry to analyze their interrelationships and to sort cells for tumorigenicity studies. Methods: Cytokeratin, CD44, and CD90 were localized to primary breast cancer and normal breast (NB) tissue by immunohistostaining and related to CD117 and CD133 expression by flow cytometry. Immunodeficient NOD.CB17-Prkdcscid/J and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice were used to test tumorigenicity of sorted CD90+ low-light scatter, CD90+ high-light scatter, and CD90neg tumor cells. Results: NB basal cells coexpressed CD44 and CD90. As cells transited luminally, CD44 was retained and downmodulated, and CD90 was lost and cytokeratin increased. In breast tumors, basal-like CD44+/ CD90+ cells were localized to the tumor periphery, adjacent to CD90+ stroma. Like normal luminal cells, interior tumor cells were CD44+/CD90-. Immunophenotyping (CD44/CD90/CD117/CD133) of cytokeratin+ cells revealed no significant difference in expression between tumors and tumor-free breast. In both, CD133 was distributed approximately equally among CD44/CD90 subsets, whereas CD117 expression was highest in the basal-associated CD44+/CD90+ subset. Sorted CD90+ pleural effusion cells with lymphoid light scatter, 49{\%} of which were CD44+, were uniquely tumorigenic in immunodeficient mice (100 cells/injection). Conclusions: Our data demonstrate that all tumors contain a small population of CD44+/CD90+ cells, mimicking the phenotype of ductal-basal cells. These are localized to the tumor periphery, adjacent to CD90+ stroma. Among the nonhematopoietic, nonmesothelial cells found in metastatic pleural effusions, low-light scatter CD90+ cells are most potently tumorigenic, compared to high-scatter CD90+ cells and CD90- cells.",
keywords = "Breast cancer, Cancer stem cells, CD117, CD133, CD44, CD90, Cytokeratin, Flow cytometry, Immunofluorescence, Immunohistochemistry",
author = "Donnenberg, {Vera S.} and Donnenberg, {Albert D.} and Ludovic Zimmerlin and Landreneau, {Rodney J.} and Rohit Bhargava and Wetzel, {Ryan A.} and Per Basse and Brufsky, {Adam M.}",
year = "2010",
month = "9",
doi = "10.1002/cyto.b.20530",
language = "English (US)",
volume = "78",
pages = "287--301",
journal = "Cytometry Part B - Clinical Cytometry",
issn = "1552-4949",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Localization of CD44 and CD90 positive cells to the invasive front of breast tumors

AU - Donnenberg, Vera S.

AU - Donnenberg, Albert D.

AU - Zimmerlin, Ludovic

AU - Landreneau, Rodney J.

AU - Bhargava, Rohit

AU - Wetzel, Ryan A.

AU - Basse, Per

AU - Brufsky, Adam M.

PY - 2010/9

Y1 - 2010/9

N2 - Background: A variety of markers have been proposed to identify breast cancer stem cells. Here, we used immunohistostaining and flow cytometry to analyze their interrelationships and to sort cells for tumorigenicity studies. Methods: Cytokeratin, CD44, and CD90 were localized to primary breast cancer and normal breast (NB) tissue by immunohistostaining and related to CD117 and CD133 expression by flow cytometry. Immunodeficient NOD.CB17-Prkdcscid/J and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice were used to test tumorigenicity of sorted CD90+ low-light scatter, CD90+ high-light scatter, and CD90neg tumor cells. Results: NB basal cells coexpressed CD44 and CD90. As cells transited luminally, CD44 was retained and downmodulated, and CD90 was lost and cytokeratin increased. In breast tumors, basal-like CD44+/ CD90+ cells were localized to the tumor periphery, adjacent to CD90+ stroma. Like normal luminal cells, interior tumor cells were CD44+/CD90-. Immunophenotyping (CD44/CD90/CD117/CD133) of cytokeratin+ cells revealed no significant difference in expression between tumors and tumor-free breast. In both, CD133 was distributed approximately equally among CD44/CD90 subsets, whereas CD117 expression was highest in the basal-associated CD44+/CD90+ subset. Sorted CD90+ pleural effusion cells with lymphoid light scatter, 49% of which were CD44+, were uniquely tumorigenic in immunodeficient mice (100 cells/injection). Conclusions: Our data demonstrate that all tumors contain a small population of CD44+/CD90+ cells, mimicking the phenotype of ductal-basal cells. These are localized to the tumor periphery, adjacent to CD90+ stroma. Among the nonhematopoietic, nonmesothelial cells found in metastatic pleural effusions, low-light scatter CD90+ cells are most potently tumorigenic, compared to high-scatter CD90+ cells and CD90- cells.

AB - Background: A variety of markers have been proposed to identify breast cancer stem cells. Here, we used immunohistostaining and flow cytometry to analyze their interrelationships and to sort cells for tumorigenicity studies. Methods: Cytokeratin, CD44, and CD90 were localized to primary breast cancer and normal breast (NB) tissue by immunohistostaining and related to CD117 and CD133 expression by flow cytometry. Immunodeficient NOD.CB17-Prkdcscid/J and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice were used to test tumorigenicity of sorted CD90+ low-light scatter, CD90+ high-light scatter, and CD90neg tumor cells. Results: NB basal cells coexpressed CD44 and CD90. As cells transited luminally, CD44 was retained and downmodulated, and CD90 was lost and cytokeratin increased. In breast tumors, basal-like CD44+/ CD90+ cells were localized to the tumor periphery, adjacent to CD90+ stroma. Like normal luminal cells, interior tumor cells were CD44+/CD90-. Immunophenotyping (CD44/CD90/CD117/CD133) of cytokeratin+ cells revealed no significant difference in expression between tumors and tumor-free breast. In both, CD133 was distributed approximately equally among CD44/CD90 subsets, whereas CD117 expression was highest in the basal-associated CD44+/CD90+ subset. Sorted CD90+ pleural effusion cells with lymphoid light scatter, 49% of which were CD44+, were uniquely tumorigenic in immunodeficient mice (100 cells/injection). Conclusions: Our data demonstrate that all tumors contain a small population of CD44+/CD90+ cells, mimicking the phenotype of ductal-basal cells. These are localized to the tumor periphery, adjacent to CD90+ stroma. Among the nonhematopoietic, nonmesothelial cells found in metastatic pleural effusions, low-light scatter CD90+ cells are most potently tumorigenic, compared to high-scatter CD90+ cells and CD90- cells.

KW - Breast cancer

KW - Cancer stem cells

KW - CD117

KW - CD133

KW - CD44

KW - CD90

KW - Cytokeratin

KW - Flow cytometry

KW - Immunofluorescence

KW - Immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=77956603259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956603259&partnerID=8YFLogxK

U2 - 10.1002/cyto.b.20530

DO - 10.1002/cyto.b.20530

M3 - Article

C2 - 20533389

AN - SCOPUS:77956603259

VL - 78

SP - 287

EP - 301

JO - Cytometry Part B - Clinical Cytometry

JF - Cytometry Part B - Clinical Cytometry

SN - 1552-4949

IS - 5

ER -